Collaborative and Other Relationships Textual (Details) $ in Thousands			1 Months Ended		3 Months Ended	12 Months Ended
	Nov. 03, 2023 USD ($) payment	Nov. 05, 2019 USD ($)	Sep. 30, 2024 USD ($) dose period	Sep. 30, 2018 USD ($) dose	Dec. 31, 2024 dose	Sep. 29, 2025 dose	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($) dose	Dec. 31, 2021 USD ($) dose	Dec. 31, 2019 USD ($) dose	Nov. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Revenues							$ 450,712	$ 331,412	$ 270,827
Torii Pharmaceutical Co
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Contract with customer, liability		$ 22,000
Potential milestone payments receivable if regulatory approval before december 31, 2021		$ 15,000
Maximum customary reduction on royalty rate		50.00%
Royalty payments receivable, expiration term from first commercial (year)		10 years
Torii Pharmaceutical Co | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Royalty rate if maintains sakigake designation		20.00%										20.00%
Torii Pharmaceutical Co | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Royalty rate if maintains sakigake designation		40.00%										80.00%
HHS Office of the Administration for Strategic Preparedness and Response
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Collaborative agreement contract value			$ 69,388
Contract term (year)			5 years
HHS Office of the Administration for Strategic Preparedness and Response | RAPIVAB
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum number of products, doses | dose			95,600
Contract term (year)			12 months
Number of optional ordering periods | period			4
Proceeds from collaborators			$ 13,878
Number of product delivered, doses | dose					2,300
Revenues							$ 1,672
HHS Office of the Administration for Strategic Preparedness and Response | RAPIVAB | Forecast
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of product delivered, doses | dose						19,100
US Department Of Health And Human Services
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Collaborative agreement contract value				$ 34,660
Contract term (year)				5 years
US Department Of Health And Human Services | RAPIVAB
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum number of products, doses | dose				50,000
Proceeds from collaborators									$ 13,864	$ 6,918	$ 13,864
Number of product delivered, doses | dose									49,980		20,000
Number of additional products, doses | dose									20,000	9,980
Clearside Biomedical, Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
License agreement, upfront payment	$ 5,000
Number of milestone payments | payment	3
Royalty payment, number of tiers | payment	3
Clearside Biomedical, Inc. | Annual Net Sales Of $2 Million
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Annual global net sales	$ 2,000,000
Clearside Biomedical, Inc. | Annual Net Sales Greater Than $1.5 Million
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Annual global net sales	1,500,000
Clearside Biomedical, Inc. | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Potential milestone payments payable	30,000
Potential milestone payments payable if regulatory approval before milestone	$ 47,500